Objective: Regular aerobic exercise leads to changesi n plasma lipids, lipoprotein and apoprotein levels. The aim of this study was to examine the training effects of the intervention program consisted of regular exercise and low fat diet on plasma lipid profile. Methods: The effects of the four weeks intervention programme which consisted of walking and dietary restriction on lipid profile in sedantary subjects were investigated. Subjects, who had dyslipidemia or obesity, were instructed to walk (consecutive 60 minutes, one times daily) and to consume no more than 20% total fat and 300 mg/d of cholesterol for four weeks. At the end of fourth week, 41 subjects who had implemented exercise-diet programme, were assigned to study (intervention) group; 21 subjects who had remained sedentary, nondieting,y were included into the control group. Total-C, triglycerides, LDL-C, HDL-C, Lp (a), apo A1 and apo B100 were measured in fasting blood samples before and after 4 weeks of intervention programme. Results: At the end of four weeks, subjects in the exercise-diet group, as compared with the control group, showed a significant reduction n body weight (respectively 1.67±2.36 kg versus -0.21±1.36 kg, p=0.001), total cholesterol (35±37 mg/dl vs - 20±25 mg/dl, p<0.001), triglycerides (30±68 mg/dl vs - 10±52 mg/dl, p=0.024) and LDL-C (29±41 mg/dl vs -18±25 mg/dl, p<0.001) levels. However, at the end of programme, in the exercise-det group, as compared with the control group, the changes in HDL-C (respectively - 0.85±7.30 mg/dl vs 1.05±5.64 mg/dl, p=0.302), Lp (a) (1.59±3.06 mg/dl vs -0.09±3.96 mg/dl, p=0.069), apo A1 (0.61±22.69 mg/dl vs - 0.66±17.27 mg/dl, p=0.822) and apo B100 (5.41±19.33 mg/dl vs - 4.00±20.51 mg/dl, p=0.080) were not significant. Conclusion: The data of this study demonstrate that the four weeks programme based on regular daily aerobic exercise and low fat diet is capable of decreasing total cholesterol, triglycerides and LDL-C levels and that this short-term invervention is insufficent in increasing HDL-C, in decreasing Lp (a) and improving apoprotein levels.